Long-term outcomes in young patients with atrioventricular b
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology.

Researchers identified all Danish patients younger than 50?years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation.

They included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years. After a median follow-up of 9.8 years, the primary endpoint had occurred in 14.9% of patients and 3.2% of controls. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint, and risk was highest early in the follow-up period.

Conclusively, atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology.

Source: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab060/6143533?rss=1
Like
Comment
Share